ClinicalTrials.gg
CompletedNCT01152190Updated May 20, 2013Results posted

A Study in Benign Prostatic Hyperplasia

A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 5 sites in 3 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2013-05-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
18th of 26
97 · median 258
Started
2010
with 2 others
Phase 3
10 of 26
none open now
Registered
12th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 18th largest by enrollment, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 12th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with benign prostatic hyperplasia
  • Provide signed at the screening
  • Agree not to use other treatment for Benign Prostatic Hyperplasia, Erectile Dysfunction or Overactive Bladder (including herbal treatments) during the study

Exclusion criteria

Exclusion Criteria

  • Have prostatic cancer or are being treated for cancer.
  • Any condition that may negatively influence the transrectal ultrasound.
  • Are being treated for heart disease with any drug that is called a nitrate (for example, nitroglycerin).
  • Any evidence of moderate to severe cardiac disease
  • Have had any of the following in the past 90 days: chest pain (called unstable angina or angina) that requires treatment, heart attack also known as myocardial infarction, heart bypass surgery (called coronary artery bypass graft surgery), had a procedure to open up blood vessels in the heart know as angioplasty or stent placement (percutaneous coronary intervention), positive cardiac stress test without effective cardiac intervention.
  • Have very high or very low blood pressure.
  • Have uncontrolled diabetes.
  • Have certain problems with your kidneys, liver, or nervous system.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    5 milligrams (mg) Tadalafil

    Drug: Tadalafil

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered orally, once daily for 8 weeks

    Also known as: Cialis, LY450190

  • DrugPlacebo

    Administered orally, once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone

    Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to blood flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone

    Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

    Time frame: Baseline, Week 4

  2. Change From Baseline to 4 and 8 Weeks in Arterial Resistive Index (RI) in the Prostate Peripheral Zone and Bladder Neck

    Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

    Time frame: Baseline, Week 4 and Week 8

  3. Change From Baseline to 4 and 8 Weeks in Color Pixel Intensity (CPI) in the Prostate Transition Zone, Peripheral Zone, and Bladder Neck

    CPI quantified blood flow in a pre-specified region of interest by using color Doppler imaging. CPI was the mean color pixel intensity in the region of interest and scores could range from 0 to 160. An increase in CPI reflected an increase in blood flow. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

    Time frame: Baseline, Week 4 and Week 8

07

Results

Posted May 20, 2013
Limitations and caveats
The primary and secondary efficacy analyses of resistive index (RI) and color pixel intensity (CPI) were based on centrally-read data.

Participant flow

Participant flow — Overall Study
MilestonePlaceboTadalafil
Started5047
Received at least 1 dose of study drug5047
Completed4539
Not completed58
Withdrew: Adverse event24
Withdrew: Death10
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject13

Outcome measures

PrimaryChange From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone

Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to blood flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · ratio
Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone
ratioPlaceboTadalafil
Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone-0.01 ± 0.0060.00 ± 0.006
Statistical analysis
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.121 (The p-value associated with the LS mean difference of change from baseline to Week 8 between the tadalafil and placebo treatment groups was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 0.01
SecondaryChange From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone

Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

Time frame:
Baseline, Week 4
Reported as:
Least squares mean · ratio
Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone
ratioPlaceboTadalafil
Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone0.00 ± 0.0060.01 ± 0.006
Statistical analysis
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.226 (The p-value associated with the LS mean difference of change from baseline to Week 4 between the tadalafil and placebo treatment groups was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 0.01
SecondaryChange From Baseline to 4 and 8 Weeks in Arterial Resistive Index (RI) in the Prostate Peripheral Zone and Bladder Neck

Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

Time frame:
Baseline, Week 4 and Week 8
Reported as:
Least squares mean · ratio
Change From Baseline to 4 and 8 Weeks in Arterial Resistive Index (RI) in the Prostate Peripheral Zone and Bladder Neck
ratioPlaceboTadalafil
Week 4 Change, Prostate Peripheral Zone (n=45, 43)0.00 ± 0.0060.01 ± 0.007
Week 8 Change, Prostate Peripheral Zone (n=43, 38)-0.01 ± 0.0060.01 ± 0.007
Week 4 Change, Bladder Neck (n=30, 30)-0.01 ± 0.0120.01 ± 0.012
Week 8 Change, Bladder Neck (n=32, 26)0.01 ± 0.0150.02 ± 0.016
Statistical analysis
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.208 (The p-value associated with the LS mean difference of change from baseline to Week 4 in the prostate peripheral zone RI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 0.01
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.066 (The p-value associated with the LS mean difference of change from baseline to Week 8 in the prostate peripheral zone RI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 0.02
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.195 (The p-value associated with the LS mean difference of change from baseline to Week 4 in bladder neck RI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 0.02
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.625 (The p-value associated with the LS mean difference of change from baseline to Week 8 in bladder neck RI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 0.01
SecondaryChange From Baseline to 4 and 8 Weeks in Color Pixel Intensity (CPI) in the Prostate Transition Zone, Peripheral Zone, and Bladder Neck

CPI quantified blood flow in a pre-specified region of interest by using color Doppler imaging. CPI was the mean color pixel intensity in the region of interest and scores could range from 0 to 160. An increase in CPI reflected an increase in blood flow. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix.

Time frame:
Baseline, Week 4 and Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4 and 8 Weeks in Color Pixel Intensity (CPI) in the Prostate Transition Zone, Peripheral Zone, and Bladder Neck
units on a scalePlaceboTadalafil
Week 4 Change, Prostate Transition Zone (n=44, 43)-2.21 ± 2.3770.42 ± 2.408
Week 8 Change, Prostate Transition Zone (n=43, 38)2.02 ± 1.9742.53 ± 2.083
Week 4 Change, Prostate Peripheral Zone (n=44, 43)-1.48 ± 2.0591.99 ± 2.091
Week 8 Change, Prostate Peripheral Zone (n=43, 38)3.11 ± 1.8682.55 ± 1.987
Week 4 Change, Bladder Neck (n=42, 40)7.37 ± 4.0223.17 ± 4.140
Week 8 Change, Bladder Neck (n=38, 36)-0.13 ± 3.6227.81 ± 3.738
Statistical analysis
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.439 (The p-value associated with the LS mean difference of change from baseline to Week 4 in the prostate transition zone CPI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 2.63
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.860 (The p-value associated with the LS mean difference of change from baseline to Week 8 in the prostate transition zone CPI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 0.51
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.240 (The p-value associated with the LS mean difference of change from baseline to Week 4 in the prostate peripheral zone CPI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 3.47
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.839 (The p-value associated with the LS mean difference of change from baseline to Week 8 in the prostate peripheral zone CPI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.55
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.468 (The p-value associated with the LS mean difference of change from baseline to Week 4 in the bladder neck CPI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -4.20
  • Placebo vs Tadalafil · Mixed-Model Repeated Measures · p = 0.131 (The p-value associated with the LS mean difference of change from baseline to Week 8 in the bladder neck CPI was tested at a significance level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: 7.93

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/50 (4%)4/50 (8%)
Tadalafil—0/47 (0%)10/47 (21.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboTadalafil
Cardiac arrestCardiac disorders1/500/47
Myocardial infarctionCardiac disorders1/500/47
Carotid artery stenosisNervous system disorders1/500/47
Ischaemic cerebral infarctionNervous system disorders1/500/47
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboTadalafil
HeadacheNervous system disorders1/504/47
Abdominal pain upperGastrointestinal disorders0/501/47
DyspepsiaGastrointestinal disorders0/501/47
Gastric disorderGastrointestinal disorders0/501/47
BronchitisInfections and infestations0/501/47
NasopharyngitisInfections and infestations0/501/47
FallInjury, poisoning and procedural complications0/501/47
Rib fractureInjury, poisoning and procedural complications0/501/47
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/501/47
NephrolithiasisRenal and urinary disorders0/501/47

Baseline characteristics

The Primary Analysis Population was defined as all randomized participants who received at least 1 dose of study medication.

Age Continuous
Age Continuous(years)PlaceboTadalafilTotal
Mean60.3 ± 8.1860.0 ± 7.5360.2 ± 7.83
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafilTotal
Female000
Male504797
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTadalafilTotal
Hispanic or Latino022
Not Hispanic or Latino504595
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTadalafilTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American8311
White414283
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PlaceboTadalafilTotal
Austria6713
Belgium459
Italy151429
United States252146
Erectile Dysfunction (ED) Etiology
Erectile Dysfunction (ED) Etiology(participants)PlaceboTadalafilTotal
Psychogenic000
Organic181533
Mixed131225
Unknown224
ED Severity
ED Severity(participants)PlaceboTadalafilTotal
Mild11920
Moderate161531
Severe6511
ED Duration
ED Duration(participants)PlaceboTadalafilTotal
<1 year415
≥1 year282856

7 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60611, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garden City, New York 11530, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10016, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Innsbruck, 6020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
09

References and documents

Publications

  • Pinggera GM, Frauscher F, Paduch DA, Bolyakov A, Efros M, Kaminetsky J, Da Pozzo L, Esler A, Cox D. Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology. 2014 Aug;84(2):412-9. doi: 10.1016/j.urology.2014.02.063. Epub 2014 Jun 14. PubMed 24938580 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2010
First posted
Jun 29, 2010
Start
Sep 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
May 20, 2013
Last update
May 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01152190
Responsible party
Sponsor
First posted
Jun 29, 2010
Start date
Sep 2010
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
May 20, 2013
Last update
May 20, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion